Regency Centers Corporation operates as a real estate investment trust. The company has market cap of $9.67 billion. The company, through its subsidiaries, owns, operates, and develops community and neighborhood shopping centers that are tenanted by grocers, category-leading anchors, specialty retailers, and restaurants. It has a 62.17 P/E ratio. As of December 31, 2006, it owned 218 retail shopping centers located in 22 states and held partial interests in 187 retail shopping centers through joint ventures located in 24 states and the District of Columbia.
Analysts expect China Biologic Products Holdings, Inc. (NASDAQ:CBPO) to report $1.11 EPS on February, 22.They anticipate $0.40 EPS change or 56.34% from last quarter’s $0.71 EPS. CBPO’s profit would be $36.78M giving it 17.82 P/E if the $1.11 EPS is correct. After having $1.11 EPS previously, China Biologic Products Holdings, Inc.’s analysts see 0.00% EPS growth. The stock increased 0.53% or $0.42 during the last trading session, reaching $79.1. About 158,220 shares traded. China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has declined 1.48% since February 12, 2017 and is downtrending. It has underperformed by 18.18% the S&P500.
The stock increased 2.02% or $1.12 during the last trading session, reaching $56.7. About 1.47 million shares traded or 51.28% up from the average. Regency Centers Corporation (REG) has declined 19.56% since February 12, 2017 and is downtrending. It has underperformed by 36.26% the S&P500.
Since January 1, 0001, it had 0 buys, and 11 sales for $117.34 million activity.
Adelante Capital Management Llc holds 4.44% of its portfolio in Regency Centers Corporation for 1.30 million shares. Sorin Capital Management Llc owns 82,800 shares or 4.08% of their US portfolio. Moreover, Cbre Clarion Securities Llc has 2.81% invested in the company for 4.10 million shares. The California-based Green Street Investors Llc has invested 2.73% in the stock. Apg Asset Management Us Inc., a New York-based fund reported 5.16 million shares.
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. The company has market cap of $2.62 billion. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. It has a 20.06 P/E ratio. The firm also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus.